Previous close | 31.11 |
Open | 31.00 |
Bid | 30.75 x 28400 |
Ask | 30.77 x 2100 |
Day's range | 30.72 - 31.41 |
52-week range | 30.22 - 65.66 |
Volume | |
Avg. volume | 3,528,012 |
Market cap | 30.219B |
Beta (5Y monthly) | 0.99 |
PE ratio (TTM) | N/A |
EPS (TTM) | -3.74 |
Earnings date | 08 Nov 2023 |
Forward dividend & yield | 2.40 (7.71%) |
Ex-dividend date | 02 May 2023 |
1y target est | 51.20 |
In this article, we will look into the 15 countries that produce the most genetically modified crops. If you want to skip our detailed analysis, you can go directly to the 5 Countries That Produce the Most Genetically Modified Crops. In the era of scientific innovation and development in practically every field, agriculture stands at […]
Bayer’s chief executive has blamed an “old chemistry mindset” and a chronic lack of investment in research by his predecessors for a thin drug pipeline that has dragged down the group’s share price. Bayer last week abandoned a trial of blood-thinner asundexian after it did not work as hoped to treat heart disease. The setback over a drug that was supposed to generate up to €5bn in annual sales at its peak caused Bayer’s already struggling stock to fall 18 per cent in a day.
Halted trial of prospective blockbuster treatment follows latest US legal blow over weedkiller Roundup